Home >> Research Area >>Neuroscience>>GluR>> VU 0364770

VU 0364770

Positive allosteric modulator at mGlu4 CAS# 61350-00-3

VU 0364770

Catalog No. BCC4597----Order now to get a substantial discount!

Product Name & Size Price Stock
VU 0364770: 5mg $46 In Stock
VU 0364770: 10mg Please Inquire In Stock
VU 0364770: 20mg Please Inquire Please Inquire
VU 0364770: 50mg Please Inquire Please Inquire
VU 0364770: 100mg Please Inquire Please Inquire
VU 0364770: 200mg Please Inquire Please Inquire
VU 0364770: 500mg Please Inquire Please Inquire
VU 0364770: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of VU 0364770

Number of papers citing our products

Chemical structure

VU 0364770

3D structure

Chemical Properties of VU 0364770

Cas No. 61350-00-3 SDF Download SDF
PubChem ID 836002 Appearance Powder
Formula C12H9ClN2O M.Wt 232.67
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (429.79 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name N-(3-chlorophenyl)pyridine-2-carboxamide
SMILES C1=CC=NC(=C1)C(=O)NC2=CC(=CC=C2)Cl
Standard InChIKey SUYUTNCKIOLMAJ-UHFFFAOYSA-N
Standard InChI InChI=1S/C12H9ClN2O/c13-9-4-3-5-10(8-9)15-12(16)11-6-1-2-7-14-11/h1-8H,(H,15,16)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of VU 0364770

DescriptionPositive allosteric modulator at mGlu4 receptors (EC50 = 290 nM in mGlu4-expressing HEK 293 cells). Reverses haloperidol-induced catalepsy in rats; prevents attentional deficit and forelimb asymmetry in a rodent model of Parkinson's disease. Exhibits affinity for MAO-B and MAO-A (Ki values are 0.72 μM and 8.5 μM respectively). Brain penetrant.

VU 0364770 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

VU 0364770 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of VU 0364770

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.2979 mL 21.4897 mL 42.9793 mL 85.9587 mL 107.4483 mL
5 mM 0.8596 mL 4.2979 mL 8.5959 mL 17.1917 mL 21.4897 mL
10 mM 0.4298 mL 2.149 mL 4.2979 mL 8.5959 mL 10.7448 mL
50 mM 0.086 mL 0.4298 mL 0.8596 mL 1.7192 mL 2.149 mL
100 mM 0.043 mL 0.2149 mL 0.4298 mL 0.8596 mL 1.0745 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on VU 0364770

VU 0364770 is a positive allosteric modulator(PAM) of mGlu4 with EC50 of 1.1 μM, exhibits insignificant activity at 68 other receptors, including other mGlu subtypes.

Featured Products
New Products
 

References on VU 0364770

[Lessons learned from the evacuation of the VU University Medical Centre after flooding].[Pubmed:28224872]

Ned Tijdschr Geneeskd. 2017;161:D861.

On 8 September 2015, flooding of the lower floors of the VU University Medical Center in Amsterdam caused serious damage to many vital technical services, such as water and power supplies. The decision was made to completely evacuate the university hospital. This paper describes the chronology and events of that day and shares a number of important lessons that were learned, in order to help readers to optimise crisis organisation in their own institutions. A serious situation or disaster can never be standardised in protocols or manuals; flexibility, improvisation and confidence in one another's expertise and commitment are therefore essential.

Why is it (also) so difficult to legislate gambling in Spain? 'Deja vu' of what occurred with alcohol.[Pubmed:27749963]

Adicciones. 2016 Oct 6;28(4):189-193.

Editorial of vol 28-4.

The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.[Pubmed:22088953]

J Pharmacol Exp Ther. 2012 Feb;340(2):404-21.

Parkinson's disease (PD) is a debilitating neurodegenerative disorder associated with severe motor impairments caused by the loss of dopaminergic innervation of the striatum. Previous studies have demonstrated that positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGlu(4)), including N-phenyl-7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxamide, can produce antiparkinsonian-like effects in preclinical models of PD. However, these early mGlu(4) PAMsexhibited unsuitable physiochemical properties for systemic dosing, requiring intracerebroventricular administration and limiting their broader utility as in vivo tools to further understand the role of mGlu(4) in the modulation of basal ganglia function relevant to PD. In the present study, we describe the pharmacologic characterization of a systemically active mGlu(4) PAM, N-(3-chlorophenyl)picolinamide (VU0364770), in several rodent PD models. VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant). When administered alone, VU0364770 exhibited efficacy in reversing haloperidol-induced catalepsy, forelimb asymmetry-induced by unilateral 6-hydroxydopamine (6-OHDA) lesions of the median forebrain bundle, and attentional deficits induced by bilateral 6-OHDA nigrostriatal lesions in rats. In addition, VU0364770 enhanced the efficacy of preladenant to reverse haloperidol-induced catalepsy when given in combination. The effects of VU0364770 to reverse forelimb asymmetry were also potentiated when the compound was coadministered with an inactive dose of L-DOPA, suggesting that mGlu(4) PAMs may provide L-DOPA-sparing activity. The present findings provide exciting support for the potential role of selective mGlu(4) PAMs as a novel approach for the symptomatic treatment of PD and a possible augmentation strategy with either L-DOPA or A2A antagonists.

Description

VU0364770 is a selective and potent positive allosteric modulator (PAM) of mGlu4. VU0346770 exhibits EC50s of 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively. VU0364770 exhibits antagonist activity at mGlu5 with a potency of 17.9 μM and PAM activity at mGlu6 with a potency of 6.8 μM. VU0364770 also possesses activity at MAO with Ki values of 8.5 and 0.72 μM for human MAO-A and human MAO-B, respectively.

Keywords:

VU 0364770,61350-00-3,Natural Products,GluR, buy VU 0364770 , VU 0364770 supplier , purchase VU 0364770 , VU 0364770 cost , VU 0364770 manufacturer , order VU 0364770 , high purity VU 0364770

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: